# A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

> **NCT02688088** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **DRUG:** Drug Cocktail
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT02688088
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-08
- **Primary completion:** 2018-02-04
- **Final completion:** 2021-01-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688088, "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02688088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*